Skip to main content


Details of the Drug
Generic Name:
Drug Type:
Bispecific CD20-directed CD3 T-cell engager
How the Drug is Given:

Injection, for intravenous use 


Indications and Usage

Glofitamab-gxbm is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. 

Side effects needing medical attention

The most common adverse reactions are cytokine release syndrome (CRS), musculoskeletal pain, rash, and fatigue. 
The most common Grade 3 to 4 laboratory abnormalities are lymphocyte count decreased, phosphate decreased, neutrophil count decreased, uric acid increased, and fibrinogen decreased.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.